Ariel Pharmaceuticals

Ariel Pharmaceuticals is a specialty pharmaceutical company that was primarily focused on the development of therapies for neurological disorders and critical care conditions. The company's lead program, AP-1531, was a proprietary nasal spray formulation of a triptan intended for the acute treatment of migraine and Complex Regional Pain Syndrome (CRPS). AP-1531 was designed to offer a rapid onset of action and improved patient outcomes over existing oral triptan therapies by utilizing a specialized delivery method. Headquartered in Broomfield, Colorado, the company reached Phase 2 clinical trials with its lead candidate. However, the company has not reported significant clinical or corporate progress in recent years, and its current operational status is considered inactive.